• Shigeto Oda, Tomohito Sadahiro, Yo Hirayama, Masataka Nakamura, Eizo Watanabe, Yoshihisa Tateishi, and Hiroyuki Hirasawa.
• Contrib Nephrol. 2010 Jan 1; 166: 47-53.

AbstractContinuous renal replacement therapy (CRRT) has been extensively used in Japan as renal support for critically ill patients managed in the ICU. In Japan, active research has also been conducted on non-renal indications for CRRT, i.e. the use of CRRT for purposes other than renal support. Various methods of blood purification have been attempted to remove inflammatory mediators, such as cytokines, in patients with severe sepsis or septic shock. In these attempts, efficacy was demonstrated for continuous hemodiafiltration(CHDF) using a polymethyl methacrylate (PMMA) membrane hemofilter which is capable of adsorbing and removing various cytokines, plasma diafiltration, and online CHDF. Furthermore, a recently developed cytokine-adsorbing column is now under clinical evaluation. Definite evidence for the efficacy of CRRT for non-renal indications has not been established. In evaluating the efficacy of CRRT for non-renal indications, it is essential to focus on patients subjected to be studied, such as severe sepsis or septic shock, and to evaluate its indication, commencement, termination of therapy and also its therapeutic effects based on analysis of blood levels of the target substances to be removed (e.g. cytokines). IL-6 blood level appears to be useful as a variable for this evaluation. It is expected that evidence endorsing the validity of these methods now being attempted in Japan will be reported near future.Copyright 2010 S. Karger AG, Basel.

14 keywords...

hide…